The VanEck Pharmaceutical ETF (PPH +1.90%) offers concentrated exposure to established global drugmakers and higher yields, while the State Street SPDR S&P Biotech ETF (XBI -0.01%) provides a diversified, higher-volatility play on smaller-cap biotechnology innovation.
Both funds offer paths into the healthcare sector but serve very different roles in a diversified portfolio. One focuses on the established stability and cash flows of global pharmaceutical giants, while the other captures the high-risk, high-reward nature of early stage biotechnology research. This analysis examines which profile fits your strategy.
Snapshot (cost & size)
| Metric | XBI | PPH |
|---|---|---|
| Issuer | SPDR | VanEck |
| Share price | $156.86 (as of 2026-08-13) | $111.52 (as of 2026-08-13) |
| Expense ratio | 0.35% | 0.36% |
| 1-yr return (as of 2026-08-13) | 76.0% | 33.6% |
| Dividend yield | 0.4% | 1.9% |
| Beta | 0.83 | 0.45 |
| AUM | $10.7 billion | $979.8 million |
Beta measures price volatility relative to the S&P 500; beta is calculated from monthly returns over the available fund history (up to five years). The 1-yr return represents total return over the trailing 12 months. Dividend yield is the trailing-12-month distribution yield.
While the management fees are virtually identical, the income profiles differ greatly. The VanEck Pharmaceutical ETF provides a significantly higher payout for income-seeking investors, offering a 1.9% yield compared to just 0.4% for the State Street SPDR S&P Biotech ETF.
Performance & risk comparison
| Metric | XBI | PPH |
|---|---|---|
| Max drawdown (5 yr) | (54.0%) | (20.3%) |
| Growth of $1,000 over 5 years (total return) | $1,267 | $1,619 |
VanEck ETF Trust – VanEck Pharmaceutical ETF
Today’s Change
(1.90%) $2.11
Current Price
$113.19
Key Data Points
AUM
$963M
Dividend Yield
1.92%
Expense Ratio
0.36%
Top Holdings
LLY
19.65%
MRK
10.28%
NVS
10.10%
What’s inside
The VanEck Pharmaceutical ETF concentrates its assets in the healthcare sector, specifically targeting companies involved in the production and sales of pharmaceuticals. Its largest positions include Eli Lilly & Co (LLY +2.68%) at 19.99%, Merck (MRK -0.58%) at 10.19%, and Novartis (NVS +1.91%) at 10.10%. With only 26 holdings, it is far more top-heavy than its biotech rival. The fund was launched in 2011. VanEck Pharmaceutical ETF has paid $2.17 per share over the trailing 12 months, which on its recent ~$111.5 share price works out to a 1.9% yield.
The State Street SPDR S&P Biotech ETF also maintains 100% healthcare exposure but employs a modified equal-weighted approach to track the S&P Biotechnology Select Industry Index. Its largest positions include Twist Bioscience (TWST -6.32%) at 1.73%, Oruka Therapeutics (ORKA -0.15%) at 1.57%, and Apogee Therapeutics Inc (APGE -0.01%) at 1.52%. It provides exposure to 155 different companies, mitigating the risk of any single clinical trial failure. The fund was launched in 2006. State Street SPDR S&P Biotech ETF has paid $0.57 per share over the trailing 12 months, which on its recent ~$156.9 share price works out to a 0.4% yield.
For more guidance on ETF investing, check out the full guide at this link.
SPDR Series Trust – SPDR S&P Biotech ETF
Today’s Change
(-0.01%) $-0.02
Current Price
$159.51
Key Data Points
AUM
$11B
Dividend Yield
0.36%
Expense Ratio
0.35%
Top Holdings
TWST
1.72%
ORKA
1.65%
APGE
1.53%
Which looks like the better buy
Pharmaceutical giants and biotechnology start-ups represent different bets on the future of medicine. Established drugmakers like Eli Lilly and Merck generate billions in revenue from products already on the market, fund their own research, and return income to shareholders along the way. The smaller biotech companies are playing a different game entirely. Most are racing to get a single drug approved, and the difference between a successful trial and a failed one can move a stock by 50% overnight.
That risk profile is baked into both funds. PPH’s concentration in proven pharmaceutical heavyweights means investors get income and relative stability, but limited exposure to the explosive upside that comes when a smaller company hits it big. XBI’s equal-weight approach across 155 primarily small-cap names means the fund captures that upside when the biotech cycle turns, and absorbs the full force of the downside when it doesn’t.
XBI has dramatically outperformed PPH over the past year, riding a strong small-cap biotech rally driven by M&A activity and a busy FDA approval calendar. For investors who want pharmaceutical income and stability, PPH is the stronger choice today. For those who believe the biotech innovation cycle has further to run, XBI is the higher-conviction, higher-risk bet.
Source link
